Kala Bio (KALA) Cash & Equivalents (2016 - 2026)

Kala Bio has reported Cash & Equivalents for 11 years, with the latest figure at $1.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 95.82% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 95.82% YoY) and the FY2025 annual result came in at $7.6 million, down 85.23% from the prior year.
• Cash & Equivalents slipped to $1.8 million in Q1 2026 per KALA's latest filing, from $7.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $70.5 million in Q4 2022 and troughed at $1.8 million in Q1 2026.
• A 5-year average of $44.6 million and a median of $49.3 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents gained 15.71% in 2023, then sank 95.82% in 2026.
• Over 5 years, Cash & Equivalents stood at $70.5 million in 2022, then dropped by 27.8% to $50.9 million in 2023, then climbed by 0.56% to $51.2 million in 2024, then sank by 85.23% to $7.6 million in 2025, then slumped by 76.66% to $1.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.8 million, $7.6 million, and $21.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.